Friday, October 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 20, 2026

Ilkka-konsernin tilinpäätöstiedote vuodelta 2025: Tilikauden liikevaihto ja oikaistu oman toiminnan liikevoitto kasvoivat

View original at globenewswire.com
Ilkka-konsernin tilinpäätöstiedote vuodelta 2025: Tilikauden liikevaihto ja oikaistu oman toiminnan liikevoitto kasvoivat Ilkka OyjTilinpäätöstiedote 20.2.2026, klo 13.00 ILKKA-KONSERNIN TILINPÄÄTÖSTIEDOTE VUODELTA 2025: Tilikauden liikevaihto ja oikaistu oman toiminnan liikevoitto kasvoivat LOKA-JOULUKUU 2025 - Liikev…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Ilkka follows active dividend policy and aims to distribute at least half of annual group result as dividends, considering result development, financial position, financing needs for profitable growth and future outlook

    80% confidence
  • SaaS services are scalable and subscription-based, forming 65% of revenue, indicating strong technology foundation and strong customer relationships

    80% confidence
  • Profinder expansion to Swedish market is progressing, with significant growth opportunities believed to exist due to high-quality data and functional user interface

    80% confidence
  • The group's goal is to grow into an international company that creates impact to improve customers' business by combining data, technology, marketing and multi-channel content production

    80% confidence
  • Associate company Kaleva Media Oy (35% ownership) will have an impact on group results and Alma Media Oyj dividend (10.9% ownership) will have significant impact on group results

    80% confidence
  • AI has been actively integrated into business and service development, with AI behind increasingly more Liana tools enabling smoother usage and better results

    80% confidence
  • The merger strengthens regional media and secures the continuity of reliable, high-quality and independent regional news media

    80% confidence
  • Year 2025 was historic and a year of major change when Ilkka's media business merged with Kaleva Media at the end of April

    80% confidence
  • Operating environment and general economic situation continued uncertain throughout 2025, but expectations for economic turnaround have strengthened as investments have been initiated in various industries

    80% confidence
  • After the reorganization, the group changed into a marketing and technology company, with operational focus now on developing this business entity

    80% confidence
  • Group's balance sheet and financial position is strong, providing good foundation to continue developing the group according to renewed strategy

    80% confidence
  • Continuing operations revenue and adjusted operating profit are expected to increase from previous year in 2026

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com